Physician profile
Sara L Collesides
NPI 1528767084
$1,335.44
in general payments reported to CMS, 2019-2025
17 companies · $578 in 2025
The $578 reported for 2025 was more than what 78% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $226 · 2024: $531 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $245.27 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $233.47 | 2023-2025 | |
| Novo Nordisk INC | $193.67 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $146.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $139.78 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $95.68 | 2024-2025 | |
| Abbott Laboratories | $43.06 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $41.21 | 2023-2024 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $38.34 | 2025 | Auvelity |
| Amgen INC. | $30.60 | 2024-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $27.67 | 2023-2024 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.24 | 2025 | Rejoyn |
| Dexcom, INC. | $16.88 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2024 | Camzyos |
| Tactile Systems Technology INC | $15.27 | 2024 | Flexitouch Plus, Entre Plus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.50 | 2024 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Collesides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.